Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1986 1
1987 1
1992 1
1997 1
2000 1
2002 2
2003 2
2004 1
2005 1
2006 4
2007 1
2008 3
2009 1
2010 2
2011 1
2012 3
2013 3
2016 3
2017 2
2018 4
2019 3
2020 3
2021 7
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
García MJ, Rivero M, Fernández-Clotet A, de Francisco R, Sicilia B, Mesonero F, de Castro ML, Casanova MJ, Bertoletti F, García-Alonso FJ, López-García A, Vicente R, Calvet X, Barreiro-de Acosta M, Ferrer Rosique J, Varela Trastoy P, Nuñez A, Ricart E, Riestra S, Arias García L, Rodríguez M, Arranz L, Pajares R, Mena R, Calafat M, Camo P, Bermejo F, Ponferrada Á, Madrigal RE, Llaó J, Sesé E, Sánchez E, Pineda Mariño JR, González Muñoza C, Carbajo López AY, Julián AB, Villoria Ferrer A, Baston-Rey I, Jara L, Almela P, Codesido L, de la Maza S, Leal C, Caballol B, Pérez-Martínez I, Vinuesa Campo R, Crespo J, Domènech E, Chaparro M, Gisbert JP. García MJ, et al. Among authors: de la maza s. J Crohns Colitis. 2024 Jan 27;18(1):65-74. doi: 10.1093/ecco-jcc/jjad124. J Crohns Colitis. 2024. PMID: 37522878
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, López-García A, Melcarne L, Rodríguez-Lago I, de la Maza S, Bouhmidi A, Barreiro-de Acosta M, López-Serrano P, Carrillo-Palau M, Mesonero F, Orts B, Bonillo D, Granja A, Guerra I. Bermejo F, et al. Among authors: de la maza s. Inflamm Bowel Dis. 2022 Jan 5;28(1):41-47. doi: 10.1093/ibd/izab015. Inflamm Bowel Dis. 2022. PMID: 33528018
Dyspnoea and dyspepsia due to a giant liver cyst.
Ispizua N, Prieto J, de la Maza S, Blanco S, Arreba P, Cabezudo P, Menéndez F, Calderón Á. Ispizua N, et al. Among authors: de la maza s. Gastroenterol Hepatol. 2021 Apr;44(4):304-305. doi: 10.1016/j.gastrohep.2020.03.019. Epub 2020 Aug 17. Gastroenterol Hepatol. 2021. PMID: 32819720 English, Spanish. No abstract available.
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, López-García A, Melcarne L, Rodríguez-Lago I, de la Maza S, Bouhmidi A, Barreiro-de Acosta M, López-Serrano P, Carrillo-Palau M, Mesonero F, Orts B, Bonillo D, Granja A, Guerra I. Bermejo F, et al. Among authors: de la maza s. Inflamm Bowel Dis. 2022 Jan 5;28(1):150. doi: 10.1093/ibd/izab242. Inflamm Bowel Dis. 2022. PMID: 34636902 No abstract available.
Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, de la Maza SS, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM. Alenda R, et al. Among authors: de la maza ss. J Neurol. 2018 Jan;265(1):24-31. doi: 10.1007/s00415-017-8625-6. Epub 2017 Oct 12. J Neurol. 2018. PMID: 29027004
45 results